Long-term functional data from Sarepta Therapeutics’ Most Advanced Gene Therapy Programs to be Presented at Upcoming Annual Congress of the World Muscle Society - Seite 2

TITLE	PROGRAM	POSTER #
Long-term Safety and Efficacy of Golodirsen in Male Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping	Golodirsen	P.283
Casimersen Treatment in Eligible Patients with Duchenne Muscular Dystrophy: Safety, Tolerability, and Pharmacokinetics Over 144 Weeks of Treatment	Casimersen	P.288
Open-Label Evaluation of Eteplirsen in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial	Eteplirsen	P.289
Delay in Duchenne Muscular Dystrophy Progression with Eteplirsen: Attenuation of Pulmonary Decline and Projected Freedom from Continuous Ventilation	Eteplirsen	P.290
Real-world Evidence of Eteplirsen Treatment Effects on Duchenne Muscular Dystrophy Related Health Outcomes Using Claims Data in the United States	Eteplirsen	P.291

Natural history and other presentations:

TITLE	POSTER #
Development of Cardiomyopathy, Respiratory Insufficiency and Loss of Ambulation in Becker Muscular Dystrophy: A Systematic Literature Review	P.41
Disease Attributes Most Important from a Societal Perspective: A Case Study Involving Duchenne Muscular Dystrophy	P.56
Identification of Disease Progression Stages in Patients with Duchenne Muscular Dystrophy Using Administrative Claims Data in the United States	P.119
The Age at Loss of Ambulation Among Patients with Limb-Girdle Muscular Dystrophy (LGMD) Subtype 2: A Systematic Review	P.142
Rasch Analysis of the Pediatric Quality of Life Inventory 4.0 Generic Core Scales Administered to Patients with Duchenne Muscular Dystrophy	P.345

Presentations will be archived under the events and presentations section of the Sarepta Therapeutics website at www.sarepta.com for one year following their presentation at WMS25.